Quercetin Inhibits Ferroptosis to Protect Hepatic Tissue in Wilson's Disease

Study Background and Research Question

Wilson’s disease (WD) is a genetic disorder characterized by defective copper metabolism, leading to toxic copper accumulation in the liver and subsequent progressive hepatic injury. The pathophysiology of WD is complex, involving not only direct copper toxicity but also oxidative stress, mitochondrial dysfunction, and cell death pathways. While ferroptosis—a regulated form of cell death driven by iron-dependent lipid peroxidation—has been implicated in metal-induced toxicity, its exact contribution to WD progression and the therapeutic potential of targeting this pathway have not been fully elucidated. The reference study (Yang et al., Phytomedicine, 2026) addresses this gap by investigating whether quercetin, a dietary flavonoid with established antioxidant and kinase-inhibitory properties, can mitigate liver injury in WD through inhibition of ferroptosis.

Key Innovation from the Reference Study

The central innovation of this study lies in its identification and mechanistic dissection of quercetin’s capacity to block ferroptosis in the context of WD-related hepatic injury. Specifically, the authors demonstrate that quercetin directly interacts with ACSL4 (acyl-CoA synthetase long-chain family member 4), a pivotal enzyme in the lipid remodeling pathway that governs susceptibility to ferroptosis. By inhibiting the ACSL4/LPCAT3/ALOX15 signaling axis, quercetin suppresses the accumulation of peroxidized phospholipids, restores redox balance, and protects hepatocytes from iron-driven cell death. This multi-level intervention positions quercetin as a unique molecular tool for dissecting ferroptotic mechanisms in hepatic pathology, expanding its recognized roles as a PI3K inhibitor and anti-inflammatory agent.

Methods and Experimental Design Insights

The study utilized a comprehensive experimental framework, employing both in vivo (Atp7b^tx-J/J mice) and in vitro (hepatocyte) models of WD. Quercetin’s efficacy was evaluated through a combination of histopathological analysis, transmission electron microscopy for mitochondrial morphology, and serum biochemistry to quantify liver injury markers. Ferroptosis was assessed by measuring hepatic iron content, lipid peroxidation (via MDA levels), glutathione metabolism, reactive oxygen species (ROS) generation, and mitochondrial membrane potential (using JC-1 dye). Lipidomics provided a high-resolution view of glycerolipid and glycerophospholipid alterations in response to treatment. Molecular mechanisms were interrogated using ACSL4 overexpression, molecular docking, molecular dynamics simulations, cellular thermal shift assays, surface plasmon resonance, RT-qPCR, Western blot, and immunofluorescence.

Protocol Parameters

• Animal model: Atp7b^tx-J/J mice, a genetic model recapitulating human WD hepatic pathology.
• Quercetin administration: Dosing regimens and duration as per in vivo protocols described in the reference study; adjust based on model specifics and desired endpoints.
• Mitochondrial membrane potential measurement: JC-1 probe staining; analyze ratio of red/green fluorescence to assess depolarization.
• Lipidomics: Employ mass spectrometry to profile glycerolipid and glycerophospholipid species.
• Ferroptosis validation: Manipulate ACSL4 expression (overexpression/knockdown) and confirm with ferroptosis-specific markers (iron assay, MDA, GPX4 levels).

Core Findings and Why They Matter

Quercetin administration led to a marked reduction in liver injury, as evidenced by improved histology, reduced serum transaminases, and preservation of mitochondrial ultrastructure (reference study). Mechanistically, quercetin suppressed hepatic iron overload, decreased ROS and lipid peroxidation, and restored glutathione homeostasis. Lipidomics revealed reversal of aberrant glycerolipid accumulation and normalization of glycerophospholipid profiles. Critically, quercetin directly bound to ACSL4, inhibiting the downstream ACSL4/LPCAT3/ALOX15 pathway and thereby attenuating the lipid peroxidation cascade central to ferroptosis. These findings provide experimental validation for targeting ferroptosis in WD and establish quercetin as a potent ferroptosis inhibitor in hepatic disease models.

Comparison with Existing Internal Articles

Previous internal reviews have emphasized quercetin’s roles as a PI3K inhibitor—highlighting its applications in cancer research, neuroinflammation, and anti-inflammatory pathways (see here; see also). The present reference study diverges by centering ferroptosis, a distinct form of cell death, as the primary mechanistic target. While earlier articles have noted quercetin’s capacity for caspase activation and cell cycle regulation in oncological models, this study extends its mechanistic repertoire to include direct modulation of lipid metabolism and iron homeostasis in the liver. Notably, the finding that quercetin binds and inhibits ACSL4 provides a molecular bridge between oxidative stress regulation and ferroptosis suppression, a nuance not previously detailed in cancer or neuroinflammation contexts. For a succinct overview of quercetin’s ferroptosis-related effects in liver models, see this internal summary.

Limitations and Transferability

While the study robustly establishes quercetin’s anti-ferroptotic and hepatoprotective effects in WD models, several limitations warrant consideration. First, translation to human clinical settings remains hypothetical, as the data are derived from animal and cellular systems. Second, the dosing, formulation, and pharmacokinetics of quercetin may differ significantly between experimental and clinical environments. Third, the multi-target nature of quercetin—as both a PI3K inhibitor and lipid metabolism modulator—raises the possibility of off-target effects. Researchers should also note that while ACSL4/LPCAT3/ALOX15 signaling appears central in WD-associated ferroptosis, distinct regulatory mechanisms may predominate in other hepatic or systemic conditions.

Research Support Resources

To replicate or extend findings on ferroptosis inhibition in liver injury models, researchers may consider Quercetin (SKU N1841) from APExBIO, a high-purity PI3K inhibitor and apoptosis modulator validated in multiple disease models. This compound is suitable for in vitro and in vivo workflows targeting ferroptosis, oxidative stress, or kinase signaling. Detailed compound specifications, including solubility and storage, can be found on the product information page. For additional mechanistic context, internal articles provide comparative analyses of quercetin’s activity across oncology, inflammation, and liver disease research.